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Abstract
In this review we describe the clinical manifestations associated with testosterone deficiency in aging men,
termed the testosterone deficiency syndrome (TDS). Since aging men suffer from multiple urological andReview;
Diagnosis;
Treatment
andrological symptoms, TDS is an important medical condition to be suspected, recognized, clinically and
biochemically diagnosed and therefore effectively and successfully treated.
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Introduction
The aim of this review is to shed more light on the importance of
recognizing the fairly common testosterone deficiency syndrome
(TDS), making the diagnosis and successfully treating patients in a
holistic, practical approach. Physiologic or naturally occurring TDS
is different from acquired TDS caused by androgen deprivation
therapy (ADT) for metastatic prostate cancer. However the effect
of testosterone deficiency on body organs may be quite similar.
In clinical practice, men over 50 years of age may present with
manifestations related to TDS and it is appropriate to recognize,
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iagnose and successfully treat it using the currently available
harmacological preparations.
efinitions
DS is a gradual age-related phenomenon that occurs in a large
roportion of the male population [1]. Whether this is due to age-
elated changes in the testosterone secreting Leydig cells (primary
ypogonadism) or changes in the hypothalamic pituitary gonadal
xis (secondary hypogonadism), it leads to decline in testosterone
roduction and circulating plasma levels [2]. The clinical mani-
estations of TDS are usually multiple and involve several body
ystems [3,4]. This term is essentially equivalent to idiopathic adult
r late onset male hypogonadism, a term that is considered a labo-
atory diagnosis rather than the clinically oriented term TDS. Other
erms describing the symptoms associated with decline in serum
estosterone levels are now falling out of favor [3,4].
nits of measurements
ense.otal testosterone (TT)
t is useful from a practical point of view to understand what we are
easuring and how it is measured before we discuss the clinical
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ture of sexual complaints in addition to lower urinary tract symptoms
(LUTS), such as diminished libido, erectile dysfunction (ED) not
responding to phosphodiesterase-5 inhibitor (PDE5-I) therapy and
shrinking phallus or testes [13,14].
Table 1 Symptoms and signs suggestive of testosterone deficiency
in men [4].
More specific
Reduced libido
Erectile dysfunction (ED)
Reduced intensity of orgasm and genital sensation
Osteoporosis or low bone mineral density
Decreased spontaneous erections
Oligospermia or azoospermia
Very small or shrinking testes
Hot flushes, sweats
Breast discomfort, gynecomastia
Loss of pubic and axillary hair, reduced shaving
Less specific
Decreased energy or vitality, increased fatigue
Depressed mood
Reduced muscle mass and strength
Poor concentration and memory04
anifestations of TDS. Great confusion has been created by the
on-standardized use of uniform serum testosterone measuring
nits [5]. In males there is a wide range of total testosterone (TT)
evels from 300 to 1000 ng/dL (10.4–35 nmol/L). Symptomatic
ecline of plasma TT below 300 ng/dL is considered diagnostic
or TDS in the United States of America (USA). This value is
quivalent to 10.4 nmol/L in SI units. One study showed that in men
ith clinically manifest decreased libido the plasma level of TT is
sually below 8 nmol/L; therefore in Europe TDS is recognized and
reated if TT falls below this level [6]. One reason for confusion in
nderstanding laboratory reports is the use of two different systems
f measurement, the conventional or English system, expressed
n ng/dL and the international system (SI), expressed in nmol/L.
he international system is a modernized version of the metric
ystem established by international agreement and is used in most
ountries. The conventional system is mainly used in the USA [5,6].
ree testosterone (FT) and free testosterone index (FTI)
ree testosterone (FT) is an active, unbound fraction of circulating
estosterone. True androgen status can be assessed either by mea-
uring the FT level or by calculating the ratio of TT concentration
o the concentration (or binding capacity) of sex hormone binding
lobulin (SHBG). This ratio, which is a useful indicator of abnor-
al androgen status, is called the free testosterone index (FTI). It is
ypically calculated on a molar/molar basis and rescaled by a factor
f ten, one hundred or one thousand, as shown below.
TI = TT (nmol/L)
SHBG (nmol/L)
he FTI is often increased in severe acne, male androgenic alope-
ia (balding), hirsutism, and other conditions in which a normal TT
evel is found with a low SHBG level. In non-obese, non-hirsute
ligomenorrheic women, an elevated FTI during the early follicular
hase is reported to be a sensitive and specific indicator for poly-
ystic ovarian disease. Most clinicians use TT measurements in the
nitial evaluation and subsequent monitoring of treatment, while FT
nd FTI are used in specialized institutions for specific cases. For
ractical reasons we recommend the use of TT in the management
f TDS [4].
nother reason for confusion is the shortcomings of the current
ssay methodologies and variation in laboratory calibration, testing
nd reporting. Therefore it is imperative to use a reliable laboratory
nd to use the same laboratory for follow-up measurements in the
linical management of patients [4–6].
elated body systems
lthough testosterone is the primary androgenic steroid hormone
esponsible for normal growth and development of male sex organs
nd maintenance of secondary sex characteristics, it is also respon-
ible for growth and function of many non-sexual organs and tissues
7]. Testosterone is the main drive for libido; it is necessary for erec-
ile function through its role in the synthesis of nitric oxide, and for
rowth and function of the prostate and seminal vesicles. Therefore
he production of adequate amounts of seminal plasma is androgen
ependent [8].H.A. Mosli
estosterone is an important hormonal stimulus for the cardiovascu-
ar and musculo-skeletal systems. Therefore, testosterone deficiency
s associated with coronary artery disease, myocardial infarction and
udden cardiac death [9]. Testosterone influences body fat distribu-
ion and limits visceral and abdominal wall adiposity; it is vital for
he adequate control of blood glucose level, and has recently been
inked to the metabolic syndrome. Thus TDS is commonly seen in
ssociation with type 2 diabetes mellitus (DM), increased central
besity, dyslipidemia and hypertension. The metabolic syndrome is
efined as the presence of central obesity (waist circumference more
han 40 in. (105 cm) for males or body mass index (BMI) more than
0 kg/m2) and two of the following criteria: type 2 DM, high blood
ressure, high triglycerides and reduced HDL cholesterol [10].
revalence
he prevalence of TDS in men older than 45 years is around 40%
11]. The Baltimore longitudinal study of aging has shown that the
revalence of hypogonadism is age-related and when a cut-off level
f 325 ng/L for TT was used, the proportion of men who were hypog-
nadal increased progressively after the age of 50 years [12]. More
en are hypogonadal by FTI than by TT after age 50, and there
eems to be a progressively greater difference, with increasing age,
etween the two criteria [12]. This is likely due to the progressive
ncrease in SHBG levels with aging [4,12].
iagnosis
linical picture
ymptoms
he diagnosis of TDS relies on the presence of the clinical manifes-
ations confirmed by the presence of low plasma TT or FT or both.
linical suspicion is based upon the symptoms and signs listed in
able 1. In the clinic, the urologist often faces a patient with a mix-Sleep disturbance; increased sleepiness
Mild anemia
Increased body fat, body mass index
Diminished physical or work performance
ome in Clinical Urology 105
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Related conditions
In addition to the urological and sexual history taking, a holistic
approach dictates a comprehensive evaluation that includes the car-
diovascular system, mainly ischemic heart disease and hypertension
[14,15]. DM is common and, if present, must be well controlled
[16]. Most clinicians can easily recognize mood changes, in partic-
ular depression. General performance, energy and muscle strength
should also be assessed. Osteoporosis manifests as bone pain, espe-
cially in the hips and vertebrae [17]. Sleep disturbances and snoring
[14] are also associated with TDS and metabolic syndrome, and
both are frequently associated with central obesity, type 2 DM,
hypertension and dyslipidemia [10].
Physical examination
The patient’s weight and height are taken, BMI is calculated, waist
circumference is measured, and pulse rate and blood pressure are
measured. Testing the hand grip assesses muscle strength in the
upper torso and testing for knee flexion/extension evaluates power
in the lower half of the body. Abdominal or central obesity is noted
and documented.
Genital examination and digital rectal examination (DRE) are
mandatory, especially when testosterone replacement therapy (TRT)
is intended. Benign prostatic hyperplasia (BPH) or DRE changes
suggestive of prostate cancer are looked for. DRE allows the esti-
mation of anal sphincter and pelvic floor muscle power. A patulous
anus or weak sphincter is noted if present. Incontinence, espe-
cially following prostatic surgery, should be documented. Stress
urinary incontinence (SUI) in the male is most commonly seen
post-prostatectomy [18,19]. It is always linked to deficient external
sphincter muscles; therefore it is reasonable to assume that older
men with TDS have a pre-existing internal sphincteric weakness
and those undergoing prostatectomy are at risk for SUI [20–23].
Laboratory tests
Coupled with the clinical picture, the diagnosis of TDS is finally
confirmed by measuring the morning fasting plasma TT level. FT
is reserved for special cases. The diagnosis of hypogonadism and
levels to indicate the initiation of treatment are illustrated in Table 2.
Summary of inter-related conditions and syndromes
See Fig. 1.Treatment
The use of oral testosterone preparations was associated with vari-
ability in absorption and liver toxicity; therefore the response was
w
s
w
i
Table 2 Cut-off levels of TT and FT for diagnosis of hypogonadism and
Plasma level
Total testosterone
Conventional units SI un
Diagnose hypogonadism ≤300 ng/dL ≤10
Initiate treatment ≤231 ng/dL ≤8 nigure 1 Summary of the TDS-related conditions and syndromes.
uboptimal, unpredictable and has fallen out of favor [24]. Sim-
larly, dermal patches were associated with skin redness, rash and
nconvenient skin reactions followed by bouts of itching that limited
atches as a treatment modality. Dermal application of gels is a
onvenient and effective method preferred by men who suffer from
eedle phobia. The use of gels avoids peaks and troughs in serum
evels. However, care must be taken to avoid contact with the female
artner, especially if pregnant, since testosterone can be easily and
uickly absorbed on contact. Limited experience was reported with
he use of buccal pellets which may cause oral irritation.
estosterones injections are of 2 types: short and long acting [7,13].
he short acting preparations are testosterone cypionate and enan-
hate oily solutions for depot use that last from 1 to 4 weeks at doses
f 100–400 mg per injection and will need frequent monitoring of
erum levels since fluctuations in peaks and troughs are expected.
he newer long acting preparation testosterone undecanoate at a
ose of 1000 mg in 4 ml can last up to 12 weeks and has the advantage
f providing a steady serum level over 6–12 weeks. The safety pro-
le of this preparation is high and it has been extensively used. When
vailable, testosterone undecanoate is the drug of choice. The course
tarts with a loading dose followed by another dose at 6 weeks then
very 6–12 weeks according to the serum testosterone level [13].
rogression/regression of TDS and duration of treatment
f left untreated, TDS will gradually and progressively manifest as
group of clinically distinct symptoms [13]. Initially it appears as
oss of libido even with the mildest degree of testosterone deficiency.
hen there will be decreased vitality, fatigue and mood swings which
ill be followed by insomnia, anemia, delayed ejaculation and
cant ejaculate volume. ED (commonly non-responsive to treatment
ith PDE5-inhibitors) follows, together with loss of muscle mass,
ncreased visceral body fat, testicular atrophy and general weak-
treatment initiation.
Free testosterone
its Conventional units SI units
.4 nmol/L ≤50 pg/dL ≤180 pmol/L
mo/L ≤0.17 nmol/L ≤72 pg/mL
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ess. Osteopenia and osteoporosis/bone pains will follow and finally
here will be loss of facial, axillary and pubic hair. Once adequate
estosterone treatment is initiated, the body needs about 3 months
o adjust its metabolic rate, hence little improvement is expected
uring the first 3 months of therapy. Following that libido will be
nhanced and there will be improved emotional well-being. Within
he next 6 months energy will increase, ED becomes reduced, and
here is increased strength, enhanced bone mineral density (BMD)
nd improved cognition. With continued therapy and maintenance
f adequate serum testosterone level, it is expected that there will
e enhanced cardiovascular health, decreased body fat and improve-
ent in some of the components of the metabolic syndrome. Optimal
mprovement would be experienced with 12 months of treatment;
herefore the course of TRT should last for at least 12 months [7,13].
onitoring
linicians should carefully monitor any man placed on TRT, espe-
ially for the development of BPH and prostate cancer. The follow-
ng tests should be periodically carried out: DRE, serum TT, PSA,
emoglobin, lipid profile, liver function tests, vitamin D3 and serum
alcium. Dosage adjustments are made, should any abnormalities
uch as polycythemia or elevated liver enzymes develop. According
o the recently reported saturation model, the pretreatment PSA will
nitially rise until all the androgen receptors are saturated, then it will
ecome steady [25]. Although androgen deprivation is essential in
he management of advanced and metastatic prostate cancer, current
vidence supports the theory that the development of prostate can-
er is related to low rather than high testosterone levels. In addition,
igh grade and aggressive prostate cancer is more common in men
hose testosterone levels are low [26].
onclusion
DS, formerly known as late-onset hypogonadism, is common and
eserves to be investigated and treated when associated with a
ide range of urological conditions. Clinicians including urologists
hould be able to manage TDS competently. TDS can be an impor-
ant component of the metabolic syndrome [10]. Endothelial disease
anifesting as ED and muscle weakness due to TDS can be a risk
actor for postoperative SUI not responsive to pelvic floor exercises,
nd should trigger screening for low serum testosterone [27]. TDS
s anticipated when ED is not responsive to PDE5-I therapy [28].
ffective therapy is available and can be safely utilized to achieve
uccessful outcomes.
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